DLQ-03 is under clinical development by Dermaliq Therapeutics and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData, Phase II drugs for Atopic Dermatitis (Atopic Eczema) have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DLQ-03’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DLQ-03 is under development for the treatment of bacterial skin and soft tissue infections (SSTIs) and atopic dermatitis. It is a broad-spectrum liquid antibiotic administered through topical route.
Dermaliq Therapeutics overview
Dermaliq Therapeutics (Dermaliq) is a private pharmaceutical company that develop a new generation of premium topical therapies and medical skin care products. The company is headquartered in United States.
For a complete picture of DLQ-03’s drug-specific PTSR and LoA scores, buy the report here.